Stephen Leeb

Stephen Leeb, Ph.D. is the Chief Investment Strategist of The Complete Investor and Real World Investing.

Dr. Leeb’s books have been notable for predicting the secular bull market that started in the 1980s (Getting in on the Ground Floor, Putnam, 1986); the tech stock crash and rise of real assets, including oil and gold (Defying the Market: Profiting in the Turbulent Post-Technology Market Boom, McGraw-Hill, 1999); and the surge in oil prices (The Oil Factor: Protect Yourself and Profit from the Coming Energy Crisis, Warner Books, 2004). His national bestseller, The Coming Economic Collapse: How You Can Thrive When Oil Costs $200 a Barrel (Warner Books, 2006), co-authored with Glen Strathy, outlined the biggest challenges facing the US economy, and accurately predicted the 2008 sub prime mortgage crisis as well as the vicious subsequent economic cycle requiring massive infusions of government stimulus, near zero interest rates and much higher federal debt levels. Game Over: How You Can Prosper in a Shattered Economy (Business Plus, 2009) predicted a permanent peak in global commodity production. Dr. Leeb’s eighth and latest book, Red Alert (Hachette, 2011), outlined China’s growing prosperity and the ways in which its demands on increasingly scarce resources threaten the American way of life.

Among his many speaking engagements, he has been the keynote speaker at both a JPMorgan Chase energy conference and a Royal Bank of Canada commodities conference.

Dr. Leeb received his bachelor’s degree in Economics from the University of Pennsylvania’s Wharton School of Business. He then earned his master’s degree in Mathematics and Ph.D. in Psychology from the University of Illinois in just three years, an academic record that stands to date. He is frequently quoted in the financial media, including Investors Business Daily, USA Today, Business Week, The New York Times, NPR and The Wall Street Journal. In addition, Dr. Leeb is a regular guest on Fox News, Bloomberg, CNN and Neil Cavuto.

Analyst Articles

A potential total return play, but not for now By Stephen Leeb Russian energy company Gazprom OAO (OGZPY), controlled by the Russian government, is at the epicenter of the current crisis radiating from Ukraine. Is there an investment case for the company, assuming a willingness to overlook an understandable distaste… Read More

Yield cos offer high income, fast growth, and green energy By Stephen Leeb This issue we’re adding an exciting and brand-new type of energy play to Growth Portfolio, one that offers investors not just the promise of long-term double-digit growth but high and growing levels of income as well. And… Read More

And China still has nearly all of them By Stephen Leeb What’s the deal with rare earth elements? Can we stop worrying about getting our hands on them? Some commentators have recently suggested that’s the case. But don’t believe it. Rare earth elements, or at least some of them—the ones… Read More

The answer lies partly in the commercial cloud By Stephen Leeb Can Microsoft (Income/Value) become a growth stock again? It’s a natural question as new leaders take the helm of the tech giant (see p.6). Company insider Satya Nadella, who headed Microsoft’s enterprise cloud services, is replacing Steve Ballmer as… Read More

A global leader in essential fast-growing markets By Stephen Leeb A few months ago (TCI October 2013, p.3) our featured monthly Spotlight stock was Ecolab, a global leader in some of the world’s fastest-growing industries including sanitation, water treatment, and the efficient use of chemicals in unconventional energy. We promised… Read More

Finding winners in a tricky arena By Stephen Leeb The U.S. spends considerably more per capita on health care than most other developed nations, without making us healthier. Obamacare didn’t create this situation, but it doesn’t solve it.  Let’s start with the big picture. One fact: in the decade starting… Read More

Helping doctors and hospitals keep costs in line By Stephen Leeb Four of the health care-related companies in our P.2 table are now Growth Portfolio picks. But what about the fifth, Cerner? After all, this is a company whose growth over the past 10 years has been dazzling, with profits… Read More

Focusing in different ways on a health care sweet spot By Stephen Leeb Two of the health care-related stocks listed on p.2 are joining Growth Portfolio. Thermo Fisher Scientific is the world’s largest manufacturer of equipment essential to biological companies, from drug makers to genetic engineering firms. It has a… Read More